TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6177264

Group type: EXPERIMENTAL
Intervention: 10% hydroxyethyl starch 200/0.5
Number of subjects: 20

Group type: COMPARATOR
Intervention: 10% dextran 40
Number of subjects: 20
Study: 31830982

Group type: EXPERIMENTAL
Intervention: Contraceptive use
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Secondary education
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Having a sexual partner within 5 years of their age
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Sexual debut at age 15 years and older
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Other race groups (White, Coloured, Indians/Asians)
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Being married
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Never given birth
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Coming from rural informal settlements
Number of subjects: 1460

Group type: EXPERIMENTAL
Intervention: Coming from rural formal settlements
Number of subjects: 1460
Study: 28657871

Group type: COMPARATOR
Intervention: Escitalopram (10 mg/day for 3 weeks, then 20 mg/day)
Number of subjects: 245

Group type: COMPARATOR
Intervention: tDCS (30-minute, 2-mA sessions for 15 weekdays, followed by 7 weekly treatments)
Number of subjects: 245

Group type: COMPARATOR
Intervention: Placebo (oral placebo)
Number of subjects: 245
Study: 25819170

Group type: EXPERIMENTAL
Intervention: Doxapram injection
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 45
Study: 24047756

Group type: EXPERIMENTAL
Intervention: A-tDCS (1 mA, 10 min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham tDCS (S-tDCS: 1 mA, 25 sec)
Number of subjects: 24
Study: 21357794

Group type: EXPERIMENTAL
Intervention: Clinical binge eaters (6% of participants)
Number of subjects: 678

Group type: EXPERIMENTAL
Intervention: Subclinical binge eaters (20% of participants)
Number of subjects: 678

Group type: COMPARATOR
Intervention: Nonovereaters and overeaters (comparison group)
Number of subjects: 678
Study: 20032908

Group type: EXPERIMENTAL
Intervention: Botulinum toxin A injections with static night splint
Number of subjects: 20

Group type: COMPARATOR
Intervention: Botulinum toxin A injections without static night splint
Number of subjects: 20
Study: 18396651

Group type: EXPERIMENTAL
Intervention: CEF-100 regimen (epirubicin 100 mg/m2, dl per 21 days for 6 cycles, n =48)
Number of subjects: 98

Group type: COMPARATOR
Intervention: CEF-60 regimen (epirubicin 60 mg/m2, dl per 21 days for 6 cycles, n = 50)
Number of subjects: 98
Study: 15274695

Group type: EXPERIMENTAL
Intervention: Short-pulse erbium:YAG laser (one pass over the entire face, two to three passes over perioral and periorbital regions)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Short-pulse erbium:YAG laser (two and three passes)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Short-pulse erbium:YAG laser
Number of subjects: 20
Study: 15297048

Group type: EXPERIMENTAL
Intervention: HPV18 L1 VLP vaccine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10524837

Group type: EXPERIMENTAL
Intervention: Lamotrigine 200 mg/day
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Lamotrigine 50 mg/day
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195
Study: 8545754

Group type: EXPERIMENTAL
Intervention: Brief scale (Outlook score and Support score)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Brief scale (Support score)
Number of subjects: 40

Group type: COMPARATOR
Intervention: HADS (Hospital Anxiety and Depression Scale)
Number of subjects: 40

Group type: COMPARATOR
Intervention: RSCL (Rotterdam Symptom Checklist)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spitzer QL‐Index
Number of subjects: 40
Study: 2254507

Group type: EXPERIMENTAL
Intervention: Spanish language condition
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2nd language condition (Spanish for English-Spanish bilinguals)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: mother tongue condition (Spanish for Spanish-English bilinguals)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Language usage (mother tongue vs 2nd language)
Number of subjects: 80
Study: 7369252

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31085503

Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffold (BVS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 66
Study: 31115345

Group type: EXPERIMENTAL
Intervention: myCompass (Web-based CBT) for 8 weeks plus a 4-week tailing-off period
Number of subjects: 780

Group type: COMPARATOR
Intervention: Active placebo intervention
Number of subjects: 780
Study: 28853210

Group type: EXPERIMENTAL
Intervention: High Slowly Digestible Starch (HSDS) breakfast
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low Slowly Digestible Starch (LSDS) breakfast
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucose solution (as a reference)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both HSDS and LSDS products
Number of subjects: 20
Study: 25641199

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl spray (INFS) 400 μg
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 24647500

Group type: EXPERIMENTAL
Intervention: 36mm metal-on-metal
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 28mm metal-on-metal
Number of subjects: 105

Group type: COMPARATOR
Intervention: 28mm metal-on-polyethylene
Number of subjects: 105
Study: 22116008

Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19406062

Group type: EXPERIMENTAL
Intervention: Left Radial (LR) approach
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Femoral (F) approach
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Right Radial (RR) approach
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: Radial approach (including LR and RR)
Number of subjects: 1005
Study: 17330681

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg) plus methotrexate
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 76
Study: 15501488

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 11929342

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400mg once daily for 7 days
Number of subjects: 401

Group type: COMPARATOR
Intervention: Cephalexin 500mg three times daily for 7 days
Number of subjects: 401
Study: 9831572

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (n = 1215)
Number of subjects: 2440
Study: 7498591

Group type: EXPERIMENTAL
Intervention: Glass ionomer base material (Base Line, De Trey Dentsply)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Negative control group (reference materials: zinc phosphate cement and reference glass ionomer base material)
Number of subjects: 0
Study: 30965392

Group type: EXPERIMENTAL
Intervention: Satavaptan (vasopressin V2 antagonist)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Satavaptan
Number of subjects: 250
Study: 28648618

Group type: EXPERIMENTAL
Intervention: H-s.c. (subcutaneous trastuzumab)
Number of subjects: 113

Group type: COMPARATOR
Intervention: H-i.v. (intravenous trastuzumab)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: H-s.c.
Number of subjects: 113

Group type: COMPARATOR
Intervention: H-i.v.
Number of subjects: 113
Study: 25892168

Group type: EXPERIMENTAL
Intervention: My Voice, My Choice (MVMC) program
Number of subjects: 83

Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 83
Study: 24176198

Group type: EXPERIMENTAL
Intervention: Diabetic, neuropathic group
Number of subjects: 23
Study: 20195031

Group type: EXPERIMENTAL
Intervention: Lidocaine alkalinized to a pH of 7.09+/‐0.10 (Group B)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lidocaine at 37 degrees C alkalinized to a pH of 6.94+/‐0.05 (Group WB)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Lidocaine at operating room temperature 18 degrees C (Group C)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lidocaine warmed to 37 degrees C (Group W)
Number of subjects: 200
Study: 17644057

Group type: COMPARATOR
Intervention: Triple therapy with rabeprazole 20mg o.d., levofloxacin 500 mg o.d., and amoxycillin 1g b.i.d. (4 tablets/day)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Quadruple therapy comprising of rabeprazole 20mg, clarithromycin 500 mg, tinidazole 500 mg plus bovine lactoferrin 200mg (10 tablets/day)
Number of subjects: 144
Study: 16372588

Group type: EXPERIMENTAL
Intervention: ACEI treatment for 4 weeks or more pre-operatively
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no ACEI treatment)
Number of subjects: 80
Study: 12225725

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 5010

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5010
Study: 10436103

Group type: EXPERIMENTAL
Intervention: Common carotid artery (CCA) diameter
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Common carotid artery (CCA) diameter in men
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Common carotid artery (CCA) diameter in women
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Intima-media (IM) thickness
Number of subjects: 104
Study: 7573844

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 2130825

Group type: EXPERIMENTAL
Intervention: tablets containing Mg citrate/Mg lactate 5 mmol three times a day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: tablets containing Mg citrate/Mg lactate and Mg hydroxide, 5 mmol three times a day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: tablets containing Mg hydroxide (Emgesan 10.3 mmol) twice a day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: solutions with Mg chloride (0.5 mmol/ml) 10 ml three times a day
Number of subjects: 18

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study: 7000224

Group type: EXPERIMENTAL
Intervention: Intravenous fluids during or after operation (Wet)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intravenous fluids (Dry)
Number of subjects: 60
Study: 31117236

Group type: EXPERIMENTAL
Intervention: Intracavernosal abobotulinumtoxinA (Dysport®) 250 or 500 U as add-on therapy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Intracavernosal abobotulinumtoxinA (Dysport®)
Number of subjects: 47
Study: 28264080

Group type: EXPERIMENTAL
Intervention: Integrated Pest Management (IPM) plus pest management education
Number of subjects: 361

Group type: COMPARATOR
Intervention: Pest management education alone (Control)
Number of subjects: 361
Study: 26545369

Group type: EXPERIMENTAL
Intervention: 12-week anti-inflammatory diet
Number of subjects: 20
Study: 23974698

Group type: EXPERIMENTAL
Intervention: Vestibular rehabilitation
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control
Number of subjects: 29
Study: 21140269

Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa (918 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Flavanol-poor cocoa
Number of subjects: 18
Study: 20023338

Group type: EXPERIMENTAL
Intervention: Long segment instrumentation with fusion (WF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Long segment instrumentation without fusion (WOF)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Both groups (WF and WOF)
Number of subjects: 42
Study: 17016059

Group type: EXPERIMENTAL
Intervention: Meloxicam (7.5 mg cumulative dose)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15288981

Group type: EXPERIMENTAL
Intervention: Accommodating IOL (1CU)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Open-loop control IOL
Number of subjects: 55

Group type: COMPARATOR
Intervention: Capsule polishing
Number of subjects: 55

Group type: COMPARATOR
Intervention: Posterior capsulorhexis
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Pilocarpine 2%
Number of subjects: 55
Study: 12206950

Group type: EXPERIMENTAL
Intervention: Seated reaching/leaning task with foot support
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Seated reaching/leaning task without foot support
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Movement direction (forward)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Movement direction (backward)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Movement direction (lateral)
Number of subjects: 12
Study: 9689507

Group type: EXPERIMENTAL
Intervention: New HF current generator with automatically controlled cut system (Endocut)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional current generator
Number of subjects: 100
Study: 7858768

Group type: EXPERIMENTAL
Intervention: Intravenous diltiazem
Number of subjects: 64

Group type: COMPARATOR
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 64
Study: 2632753

Group type: EXPERIMENTAL
Intervention: Angiotensin II (0.5, 1.0, and 2.0 ng/kg per min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Noradrenaline (subthreshold doses)
Number of subjects: 19
Study: 47280

Group type: EXPERIMENTAL
Intervention: Indoprofen 200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indoprofen 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient preferences
Number of subjects: 0
Study: 30321318

Group type: EXPERIMENTAL
Intervention: 75 g force
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 150 g force
Number of subjects: 15

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 15
Study: 27613906

Group type: EXPERIMENTAL
Intervention: Self-affirmation (reflecting on personal values and positive traits using a questionnaire)
Number of subjects: 265

Group type: COMPARATOR
Intervention: Matched control condition (no self-affirmation)
Number of subjects: 265
Study: 26023212

Group type: EXPERIMENTAL
Intervention: lopinavir/ritonavir monotherapy (arm A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: lopinavir/ritonavir+zidovudine/lamivudine tritherapy (arm B)
Number of subjects: 34
Study: 24308770

Group type: EXPERIMENTAL
Intervention: Partner presence
Number of subjects: 24

Group type: COMPARATOR
Intervention: Partner absence
Number of subjects: 24
Study: 22128296

Group type: EXPERIMENTAL
Intervention: FSH (starting dose 50 IU for up to three treatment cycles)
Number of subjects: 302

Group type: COMPARATOR
Intervention: CC (50‐150 mg/day for 5 days)
Number of subjects: 302
Study: 19239405

Group type: EXPERIMENTAL
Intervention: One‐to‐one pre‐ and postnatal breastfeeding education and support from a lactation consultant
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard breastfeeding services (Control)
Number of subjects: 104
Study: 17897270

Group type: EXPERIMENTAL
Intervention: Sevoflurane (inspired concentrations varying from 2% to 5%)
Number of subjects: 33

Group type: COMPARATOR
Intervention: No medication (preoxygenation with 100% oxygen alone)
Number of subjects: 33
Study: 16305601

Group type: EXPERIMENTAL
Intervention: Neurologist consultation
Number of subjects: 38

Group type: COMPARATOR
Intervention: Community care physicians (CCPs)
Number of subjects: 38
Study: 11912385

Group type: EXPERIMENTAL
Intervention: Abarelix depot 100 mg
Number of subjects: 255

Group type: COMPARATOR
Intervention: Leuprolide acetate 7.5 mg plus bicalutamide 50 mg daily
Number of subjects: 255
Study: 10217442

Group type: EXPERIMENTAL
Intervention: Multiple Signal Classification (MUSIC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Principal Component Analysis (PCA)
Number of subjects: 0
Study: 7815657

Group type: EXPERIMENTAL
Intervention: Basic version of scenarios (2 options)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Expanded version of scenarios (3 options)
Number of subjects: 680
Study: 2128988

Group type: EXPERIMENTAL
Intervention: Mastectomy plus adjuvant ovariectomy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Mastectomy only
Number of subjects: 34
Study: 573763

Group type: EXPERIMENTAL
Intervention: Time-limited therapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Time-unlimited therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Time-limited and open-ended therapy (follow-up)
Number of subjects: 42
Study: 31891407

Group type: EXPERIMENTAL
Intervention: Tart cherry juice concentrate (7.5 ml, 15 ml, 22.5 ml, or 30 ml twice daily for 28 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 29235560

Group type: EXPERIMENTAL
Intervention: Milk (1.5 g fat/100 mL)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sugar-sweetened soft drinks (SSSD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Non-caloric soft drink (NCSD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 60
Study: 27686642

Group type: EXPERIMENTAL
Intervention: Oxycodone (0.1 mg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl (0.001 mg/kg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dezocine (0.1 mg/kg)
Number of subjects: 60
Study: 25424209

Group type: EXPERIMENTAL
Intervention: Diaper cream applied twice daily (group II)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Wet wipes and diaper cream applied twice daily (group III)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Water-moistened washcloths at diaper changes (group I)
Number of subjects: 89
Study: 22561463

Group type: EXPERIMENTAL
Intervention: Instructor led training
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Limited instructor with manikin feedback
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Self-directed learning
Number of subjects: 214
Study: 21029013

Group type: EXPERIMENTAL
Intervention: Acetylcholine (intra-arterial, endothelium-dependent vasodilator)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Sodium nitroprusside (intra-arterial, endothelium-independent vasodilator)
Number of subjects: 115
Study: 18418454

Group type: EXPERIMENTAL
Intervention: Nitazoxanida 500mg every 12 hours for 3 days
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo every 12 hours for 3 days
Number of subjects: 120
Study: 15812303

Group type: EXPERIMENTAL
Intervention: Bipolar patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy male controls
Number of subjects: 32
Study: 12431929

Group type: EXPERIMENTAL
Intervention: Rectal Teaching Associate (RTA)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Lecture and simulated model
Number of subjects: 65
Study: 10499136

Group type: EXPERIMENTAL
Intervention: Intervention course designed to promote physical activity
Number of subjects: 338
Study: 8734175

Group type: EXPERIMENTAL
Intervention: Nonsynchronized burst pacing
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Synchronized burst pacing
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ramp pacing
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Universal pacing
Number of subjects: 38
Study: 1661762

Group type: EXPERIMENTAL
Intervention: Angiotensin II/isoprenaline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isoprenaline
Number of subjects: 10

Group type: COMPARATOR
Intervention: Angiotensin II
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 7161138

Group type: EXPERIMENTAL
Intervention: Tablets containing 70.0 mg ascorbic acid, 2.0 mg riboflavin, and 2.0 mg pyridoxine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control groups
Number of subjects: 0
Study: 30584120

Group type: EXPERIMENTAL
Intervention: Pressure release
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Phonophoresis with betamethasone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 60
Study: 28379325

Group type: EXPERIMENTAL
Intervention: Resistance Training + Caloric Restriction (RT+CR)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Aerobic Training + Caloric Restriction (AT+CR)
Number of subjects: 123
Study: 25915628

Group type: EXPERIMENTAL
Intervention: FRF treatment at 67 °C for 3 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FRF treatment at 62 °C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FRF treatment at 52 °C-57 °C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FRF treatment at 62 °C to 67 °C
Number of subjects: 0
Study: 25531046

Group type: EXPERIMENTAL
Intervention: Aflibercept 6 mg/kg plus docetaxel 75 mg/m²
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Aflibercept 4 mg/kg plus docetaxel 75 mg/m²
Number of subjects: 20
Study: 22262486

Group type: EXPERIMENTAL
Intervention: Epoetin and IV ferric gluconate
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Epoetin and oral ferrous sulfate
Number of subjects: 187

Group type: COMPARATOR
Intervention: Epoetin and no iron
Number of subjects: 187
Study: 19927684

Group type: EXPERIMENTAL
Intervention: Direct instruction
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Feedback
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Repeated exposure
Number of subjects: 66
Study: 17311986

Group type: EXPERIMENTAL
Intervention: Probiotic guidelines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidelines for the Evaluation of Probiotics in Food
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Codex draft on health and nutrition claims
Number of subjects: 0
Study: 15249716

Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO)
Number of subjects: 12
Study: 11784739

Group type: EXPERIMENTAL
Intervention: Scopolamine (muscarinic receptor antagonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9846709

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (rHuEpo) administered subcutaneously for 15 days along with iron and folic acid.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group receiving only iron and folic acid.
Number of subjects: 20
Study: 7813219

Group type: EXPERIMENTAL
Intervention: Marvelon (150 micrograms desogestrel + 30 micrograms ethinylestradiol)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Femovan (75 micrograms gestodene + 30 micrograms ethinylestradiol)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Both Marvelon and Femovan
Number of subjects: 2